Clinical Trial Update: An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating whether adding the 5-HT2A antagonist M100907 to citalopram improves outcomes in treatment-resistant depression; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• Citalopram (Citalopram hydrobromide)
• M100907 (MDL-100,907)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Depressive Disorder | Phase 2 | Status: COMPLETED